Anti Cd 20 Ocrevus denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ocrevus on Quantity-Limit Grounds

Aetna's quantity-limit denial for Ocrevus (ocrelizumab) means the plan has approved the drug in principle but has capped the number of doses, infusions, or units it will cover within a given authorization period. For Ocrevus, which is administered by intravenous infusion on a specific schedule per the FDA-approved label, a quantity-limit denial commonly occurs when the requested quantity exceeds the default limit coded into Aetna's benefit system — even when the prescribed quantity is entirely consistent with the FDA label and standard of care.

The key argument in this appeal is that the prescribed quantity matches the FDA-approved dosing regimen. You do not need to argue for more than the label supports; you need to show that what was prescribed IS what the label supports.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 or ACA rules within the timeframe on your denial letter. Quantity-limit denials are clinical determinations and are fully appealable.
• External review: Under ACA §2719, if the internal appeal fails, an IRO will independently evaluate whether the quantity limit is consistent with generally accepted standards of medical practice and the FDA label. This is a strong external-review category when the prescribed quantity mirrors the label.
• Expedited review: Available if the quantity limit would result in a missed infusion that poses a serious health risk — for example, an annual or maintenance dose that cannot be delayed without clinical consequence.

## What to Gather

1. FDA-approved prescribing label — download from DailyMed. Print the "Dosage and Administration" section. Do not cite specific numbers in your letter; instead, state that the prescribed quantity is consistent with the FDA-approved regimen and attach the label as an exhibit. 2. Prescriber order — the actual prescription or infusion order showing the requested quantity and schedule. 3. Neurologist medical-necessity letter — the prescriber should state that the requested quantity matches the FDA-labeled regimen for the patient's MS subtype and that reducing the quantity would constitute a deviation from the standard of care. 4. Prior infusion history (for renewals) — if this is a continuation of existing therapy, document the infusion history to show the patient has received this regimen previously without safety issue. 5. Aetna's quantity-limit policy — identify the specific limit that was applied and compare it against the FDA label.

## Criteria-Mapping Structure

| Quantity-Limit Basis | Rebuttal Documentation | |---|---| | Requested quantity exceeds plan default | FDA label dosing section (attached as exhibit) | | Prescribed schedule not matching limit | Prescriber order + neurologist letter | | Renewal: ongoing clinical need | Most recent neuro visit note; infusion history | | Expedited need (if applicable) | Neurologist urgency statement |

Frame your appeal letter around a single clear point: the requested quantity is the quantity specified in the FDA-approved label for this indication and MS subtype. Attach the label. Attach the prescribing order. Any quantity limit that falls below the label-specified regimen is, by definition, inconsistent with the FDA-approved standard of care.